Angiogenesis Inhibitors

"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Descriptor ID	D020533
MeSH Number(s)	D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
Concept/Terms	Angiogenesis Inhibitors Angiogenesis Inhibitors Neovascularization Inhibitors Angiogenic Antagonists Angiogenic Inhibitors Angiostatic Agents Agents, Angiostatic Antagonists, Angiogenic Anti-Angiogenetic Agents Agents, Anti-Angiogenetic Anti Angiogenetic Agents Anti-Angiogenic Drugs Anti Angiogenic Drugs Drugs, Anti-Angiogenic Antiangiogenic Agents Agents, Antiangiogenic Inhibitors, Angiogenesis Inhibitors, Angiogenetic Inhibitors, Angiogenic Inhibitors, Neovascularization Angiogenetic Antagonists Antagonists, Angiogenetic Angiogenetic Inhibitors Angiogenesis Factor Inhibitors Angiogenesis Factor Inhibitors Factor Inhibitors, Angiogenesis Inhibitors, Angiogenesis Factor Anti-Angiogenesis Effect Anti-Angiogenesis Effect Anti Angiogenesis Effect Effect, Anti-Angiogenesis Antiangiogenesis Effect Effect, Antiangiogenesis Antiangiogenesis Effects Effects, Antiangiogenesis Anti-Angiogenesis Effects Anti Angiogenesis Effects Effects, Anti-Angiogenesis

Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Growth Substances [D27.505.696.377]
Angiogenesis Modulating Agents [D27.505.696.377.077]
Angiogenesis Inhibitors [D27.505.696.377.077.099]
Growth Inhibitors [D27.505.696.377.450]
Angiogenesis Inhibitors [D27.505.696.377.450.100]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Angiogenesis Inhibitors [D27.505.954.248.025]

Below are MeSH descriptors whose meaning is related to "Angiogenesis Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.

Bar chart showing 46 publications over 21 distinct years, with a maximum of 4 publications in 2011 and 2012 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	1	0	1
2003	1	0	1
2004	2	0	2
2005	1	1	2
2006	1	0	1
2007	1	1	2
2008	1	1	2
2009	2	1	3
2010	1	1	2
2011	2	2	4
2012	3	1	4
2013	2	0	2
2014	1	2	3
2015	2	1	3
2016	2	0	2
2017	2	0	2
2018	1	2	3
2019	3	1	4
2021	1	0	1
2023	0	1	1

Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.

Yousuf SJ, Ma J, Nelson L, Chen M, Weldeslase TA, Akinyemi OA. Neovascular Age-Related Macular Degeneration in a Predominantly Black Population. Ophthalmic Surg Lasers Imaging Retina. 2023 10; 54(10):580-584.

View in: PubMed
Gangapuram M, Eyunni S, Zhang W, Redda KK. Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents. Anticancer Agents Med Chem. 2021; 21(18):2505-2511.

View in: PubMed
Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, Sutariya V. An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration. AAPS PharmSciTech. 2019 Aug 09; 20(7):281.

View in: PubMed
Natarajan G, Shankaran S, Nolen TL, Sridhar A, Kennedy KA, Hintz SR, Phelps DL, DeMauro SB, Carlo WA, Gantz MG, Das A, Greenberg RG, Younge NE, Bliss JM, Seabrook R, S?nchez PJ, Wyckoff MH, Bell EF, Vohr BR, Higgins RD. Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment. Pediatrics. 2019 08; 144(2).

View in: PubMed
M?rquez-Garb?n DC, Gorr?n-Rivas M, Chen HW, Sterling C, Elashoff D, Hamilton N, Pietras RJ. Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression. Cancer Lett. 2019 05 01; 449:66-75.

View in: PubMed
Mansukhani SA, Hutchinson AK, Neustein R, Schertzer J, Allen JC, Hubbard GB. Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression. Ophthalmol Retina. 2019 05; 3(5):436-443.

View in: PubMed
Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, McGregor ML, Jordan CO, Mantagos IS, Bell EF, Kraker RT. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. Ophthalmology. 2018 12; 125(12):1961-1966.

View in: PubMed
Wu CM, Wu AM, Greenberg PB, Yu F, Lum F, Coleman AL. Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries. Ophthalmic Surg Lasers Imaging Retina. 2018 04 01; 49(4):241-244.

View in: PubMed
Rathinavelu A, Kanagasabai T, Dhandayuthapani S, Alhazzani K. Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models. Oncol Rep. 2018 Apr; 39(4):1711-1724.

View in: PubMed
Rathinavelu A, Alhazzani K, Dhandayuthapani S, Kanagasabai T. Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor. Tumour Biol. 2017 Nov; 39(11):1010428317726841.

View in: PubMed

People

Explore

Similar Concepts

Top Journals